Document is current
Any future updates will be listed below
-
Authors
Birocchi, Filippo
Almazan, Antonio J. https://orcid.org/0009-0003-4947-3968
Parker, Aiyana https://orcid.org/0009-0001-9037-641X
Bouffard, Amanda A.
Goncalves, Sadie
Kelly, Christopher https://orcid.org/0009-0006-6220-4588
Frank, Jessica https://orcid.org/0000-0001-5334-3240
Leick, Mark B. https://orcid.org/0000-0003-3111-0221
Haradhvala, Nicholas J. https://orcid.org/0000-0003-1113-3135
Kagawa, Shaw https://orcid.org/0000-0002-9943-3855
Getz, Gad https://orcid.org/0000-0002-0936-0753
Escobar, Giulia https://orcid.org/0000-0001-9177-0251
Salas-Benito, Diego
Mucci, Adele
Berger, Trisha R.
Maus, Marcela V. https://orcid.org/0000-0002-7578-0393
-
Funding
Funding for this research was provided by:
EIF | Stand Up To Cancer
American-Italian Cancer Foundation
Associazione Italiana per la Ricerca sul Cancro
- License Information
-
More Information
Article History
Received: 19 November 2024
Accepted: 2 July 2025
First Online: 1 November 2025
Competing interests
: MVM is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab and Luminary) and University of Pennsylvania (some licensed to Novartis). MVM receives Grant/Research support from: Kite Pharma, Moderna, Sobi. MVM has served as a consultant for multiple companies involved in cell therapies. MVM holds Equity in 2SeventyBio, A2Bio, Affyimmune, BendBio, Cargo, GBM newco, Model T bio, Neximmune, Oncternal. MVM serves on the Board of Directors of 2Seventy Bio. None of the above is directly relevant to the data presented in this manuscript. The remaining authors declare no competing interests.
